Natera Inc.

Natera, Inc. is a diagnostics company specializing in cell-free DNA (cfDNA) testing across oncology, women's health and organ transplant monitoring. The company develops and commercializes molecular diagnostic tests that analyze fragments of DNA circulating in the bloodstream, providing non-invasive insights into genetic conditions, cancer status and transplant health without requiring tissue biopsies.

Natera's product portfolio includes Panorama, a non-invasive prenatal screening test that detects chromosomal abnormalities from a maternal blood draw; Horizon, a carrier screening test that identifies inherited genetic conditions; Signatera, a tumor-informed molecular residual disease test used in oncology to monitor cancer recurrence; and Prospera, which detects organ transplant rejection by measuring donor-derived cfDNA in recipient blood. Each test applies the company's core cfDNA analysis platform to a different clinical application.

The company's technology integrates molecular biology, bioinformatics and machine learning to achieve high sensitivity and specificity in detecting genetic signals from small DNA fragments. Natera operates CAP-accredited and CLIA-certified laboratories and has supported its clinical claims through peer-reviewed research. The company serves oncologists, obstetricians, genetic counselors and transplant physicians, providing diagnostic information that supports treatment decisions and patient monitoring. Natera trades on Nasdaq under the ticker NTRA.